Tardive Dyskinesia and Psychiatric Illness

Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).

Joseph Goldberg, MD Roger McIntyre, MD, FRCPC Released: May 24, 2021

Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.

Leslie Citrome, MD, MPH Joseph P. McEvoy, MD Released: June 11, 2021

John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.

John M. Kane, MD Rebecca S. Roma, MD Released: July 20, 2021

The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.

Joseph P. McEvoy, MD Released: May 4, 2021

Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.

Rif S. El-Mallakh, MD Released: June 8, 2021

Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.

Jonathan M. Meyer, MD Released: July 8, 2021

Formulate an approach to select the right treatment for patients with tardive dyskinesia.

Manish Kumar Jha, MD Released: June 17, 2021

Formulate an approach to diagnose patients with tardive dyskinesia.

Greg Mattingly, MD Released: June 21, 2021